Activities of New Antimicrobial Agents (Trovafloxacin, Moxifloxacin, Sanfetrinem, and Quinupristin-Dalfopristin) against Bacteroides fragilis Group: Comparison with the Activities of 14 Other Agents

Abstract

The antimicrobial activities of trovafloxacin, moxifloxacin, sanfetrinem, quinupristin-dalfopristin, and 14 other antimicrobial agents against 218 Bacteroides fragilis group strains were determined. A group of 10 imipenem-resistant strains were also tested. Imipenem, meropenem, and sanfetrinem had the lowest MICs of all of the β-lactams. Quinupristin-dalfopristin inhibited all of the strains at 2 μg/ml. Overall, the MICs of trovafloxacin and moxifloxacin for 90% of the strains tested were 1 and 2 μg/ml, respectively.

Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe

“…Susceptibility testing of anaerobes is not generally used for clinical decision‐making, because of the slow growth of the bacteria, the polymicrobial nature of anaerobic infections, the cost and complexity of the testing methods and the belief that susceptibility patterns among anaerobes are predictable. Several reports indicate an increase of antimicrobial resistance in anaerobic bacteria, especially among the B. fragilis group [7,9–17]. However, there is also one report demonstrating a decrease of resistance in the B. fragilis group during the past years, with the exception for cefoxitin and clindamycin [18].…”

National Survey on the Susceptibility ofBacteroides fragilisGroup: Report and Analysis of Trends for 1997–2000

“…Recent publications have listed the results of susceptibility for the various species, classifying the isolates as B. fragilis and nonfragilis [10][11][12][13]. Thus, the need for another level of testing has evolved.…”

The Medically Important Bacteroides spp. in Health and Disease

“…The values given for the individual species are for % resistant strains only. Data were from the following studies: Am1 (Aldridge et al, 2001), Am2 (Snydman et al, 1999), Spa (Betriu et al, 1999a), Sp2 (Betriu et al, 1999b), and SA (Lubbe et al, 1999). to carbapenems has been restricted primarily to B. fragilis isolates, which contain the cfiA blactamase gene and will be discussed in the section Mechanisms of Resistance.…”